Salama H, Zekri ARN, Bahnassy AA, Medhat E, Halim HA, Ahmed OS, Mohamed G, Alim SAA, Sherif GM. Autologous CD34+ and CD133+ stem cells transplantation in patients with end stage liver disease. World J Gastroenterol 2010; 16(42): 5297-5305 [PMID: 21072892 DOI: 10.3748/wjg.v16.i42.5297]
Corresponding Author of This Article
Abdel-Rahman N Zekri, Professor, Virology and Immunology Unit, Cancer Biology Department, National Cancer Institute, Cairo University, Kasr Al-Aini st., Fom El-Khaleeg, 11976 Cairo, Egypt. ncizekri@yahoo.com
Article-Type of This Article
Original Article
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Gastroenterol. Nov 14, 2010; 16(42): 5297-5305 Published online Nov 14, 2010. doi: 10.3748/wjg.v16.i42.5297
Autologous CD34+ and CD133+ stem cells transplantation in patients with end stage liver disease
Hosny Salama, Abdel-Rahman N Zekri, Abeer A Bahnassy, Eman Medhat, Hanan A Halim, Ola S Ahmed, Ghada Mohamed, Sheren A Al Alim, Ghada M Sherif
Hosny Salama, Eman Medhat, Hanan A Halim, Ghada Mohamed, Sheren A Al Alim, Tropical Medicine Department, El-Kasr Al-Aini School of Medicine, Kasr Al-Aini st., Kasr Al-Aini, 11977 Cairo, Egypt
Abdel-Rahman N Zekri, Ola S Ahmed, Virology and Immunology Unit, Cancer Biology Department, National Cancer Institute, Cairo University, Kasr Al-Aini st., Fom El-Khaleeg, 11976 Cairo, Egypt
Abeer A Bahnassy, Pathology Department, National Cancer Institute, Cairo University, Kasr Al-Aini st., Fom El-Khaleg, 11976 Cairo, Egypt
Ghada M Sherif, Biostatistics and Epidemiology Department, National Cancer Institute, Cairo University, 11976 Cairo, Egypt
Author contributions: Salama H and Zekri ARN contributed equally to this work and also designed the research; Salama H, Zekri ARN, Bahnassy AA, Medhat E, Halim HA, Ahmed OS, Mohamed G and Al Alim SA performed the research and contributed new reagents/analytic tools; Sherif GM analyzed the data; Salama H, Zekri ARN and Bahnassy AA wrote the paper.
Supported by Grand Office of Cairo University
Correspondence to: Abdel-Rahman N Zekri, Professor, Virology and Immunology Unit, Cancer Biology Department, National Cancer Institute, Cairo University, Kasr Al-Aini st., Fom El-Khaleeg, 11976 Cairo, Egypt. ncizekri@yahoo.com
Telephone: +20-2-22742607 Fax: +20-2-23644720
Received: June 3, 2010 Revised: July 6, 2010 Accepted: July 13, 2010 Published online: November 14, 2010
Abstract
AIM: To assess the utility of an autologous CD34+ and CD133+ stem cells infusion as a possible therapeutic modality in patients with end-stage liver diseases.
METHODS: One hundred and forty patients with end-stage liver diseases were randomized into two groups. Group 1, comprising 90 patients, received granulocyte colony stimulating factor for five days followed by autologous CD34+ and CD133+ stem cell infusion in the portal vein. Group 2, comprising 50 patients, received regular liver treatment only and served as a control group.
RESULTS: Near normalization of liver enzymes and improvement in synthetic function were observed in 54.5% of the group 1 patients; 13.6% of the patients showed stable states in the infused group. None of the patients in the control group showed improvement. No adverse effects were noted.
CONCLUSION: Our data showed that a CD34+ and CD133+ stem cells infusion can be used as supportive treatment for end-stage liver disease with satisfactory tolerability.
